View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMynaric 향후 성장Future 기준 점검 2/6Mynaric은 연간 수입과 매출이 각각 37.5%와 79.4% 증가할 것으로 예상되고 EPS는 연간 38.7%만큼 증가할 것으로 예상됩니다.핵심 정보37.5%이익 성장률38.71%EPS 성장률Aerospace & Defense 이익 성장26.1%매출 성장률79.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트19 Dec 2024최근 향후 성장 업데이트공시 • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.공시 • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.공시 • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.모든 업데이트 보기Recent updates공시 • Feb 18+ 1 more updateMynaric AG(NasdaqGS:MYNA) dropped from NASDAQ Composite IndexMynaric AG has been dropped from the NASDAQ Composite Index.공시 • Feb 14Mynaric Announces Receipt of Delisting Notice from NasdaqMynaric announced that it received a delisting notification dated February 10, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market Inc. As previously disclosed, on February 7, 2025, Mynaric's management board, with the approval of its supervisory board, resolved on a financial restructuring by proceedings under the German Corporate Stabilization and Restructuring Act (Gesetz über den Stabilisierungs- und Restrukturierungsrahmen für Unternehmen) and notified the competent Munich Local Court - Restructuring Court - of such restructuring project (the "StaRUG Proceeding").On February 10, 2025, Mynaric received the Delisting Notice from Nasdaq notifying Mynaric that, as a result of the StaRUG Proceeding and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that Mynaric's American Depositary Shares representing its ordinary shares (the "ADS") will be delisted from Nasdaq. The Delisting Notice also advises Mynaric of its right to appeal Nasdaq's determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. Mynaric does not intend to pursue an appeal. Trading of the ADS will be suspended at the opening of business on February 18, 2025. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the ADS from listing and registration on Nasdaq. Nasdaq has previously notified Mynaric that it is no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) for failing to maintain a minimum market value of $50 million in listed securities, (ii) Nasdaq Listing Rule 5250(c)(2) for not filing an interim balance sheet and income statement as of and for the end of its second quarter on Form 6-K within six months following the end of Mynaric's second quarter, (iii) Nasdaq Listing Rule 5620(a) for failing to hold an annual meeting of shareholders within twelve months after the end of the Mynaric's fiscal year, and (iv) Nasdaq Listing Rule 5450(a)(1) for not meeting the minimum closing bid price of $1.00 per share of the ADS.공시 • Jan 16Mynaric AG, Annual General Meeting, Feb 21, 2025Mynaric AG, Annual General Meeting, Feb 21, 2025, at 10:00 W. Europe Standard Time.공시 • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.공시 • Nov 05Mynaric AG, Annual General Meeting, Dec 11, 2024Mynaric AG, Annual General Meeting, Dec 11, 2024, at 10:00 W. Europe Standard Time.공시 • Nov 01Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Files Against Mynaric AGBronstein, Gewirtz & Grossman, LLC announced that a class action lawsuit has been filed against Mynaric AG (Mynaric) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mynaric securities between June 20, 2024, and October 7, 2024, inclusive (Class Period). The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) lower-than-expected production yields and component supplier shortages of key components were causing production delays for Mynaric's CONDOR Mk3 product; (2) the foregoing issues were likely to have a material negative impact on the Company's revenue growth and cause the Company to incur an operating loss; (3) as a result, Mynaric was unlikely to meet its own previously issued financial guidance for fiscal year 2024; (4) accordingly, the Company's business and/or financial prospects were overstated; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.공시 • Oct 08Mynaric Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed SecuritiesMynaric AG announced that it received a notification letter dated October 2, 2024 (the ‘Deficiency Letter’) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the ‘Nasdaq’) notifying that Mynaric is no longer in compliance with the Nasdaq continued listing criteria, including the Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum of $50 million in market value of listed securities (the ‘MVLS Requirement’). Nasdaq also determined that Mynaric does not meet the alternatives of total assets and total revenue for continued listing. The Deficiency Letter has no immediate effect on the listing of Mynaric’s American Depositary Shares representing its ordinary shares (the ‘ADS’), which continue to trade under the symbol ‘MYNA.’ The Deficiency Letter provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), Mynaric has a period of 180 calendar days from the date of the Deficiency Letter, or until March 31, 2025, to regain compliance with the MVLS Requirement. During this period, the ADS will continue to trade on Nasdaq. Nasdaq will deem Mynaric to have regained compliance with the MVLS Requirement if at any time during this compliance period Mynaric’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days. In the event Mynaric does not regain compliance with the MVLS Requirement by March 31, 2025, Mynaric will receive written notification from Nasdaq that Mynaric’s ADS are subject to delisting. At that time, Mynaric may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if Mynaric does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such event, Mynaric may also seek to apply for a transfer to The Nasdaq Capital Market if it meets the requirements for continued listing thereon. Mynaric is reviewing its options for regaining compliance with the MVLS Requirement and for remedying other future potential non-compliances with Nasdaq continued listing requirements. There can be no assurance that Mynaric will be able to regain compliance with the MVLS Requirement or other Nasdaq continued listing requirements in a timely fashion, in which case its securities would be delisted from Nasdaq.공시 • Sep 17Mynaric Advances Production of CONDOR Mk3Mynaric announced the successful advancement of the company's volume production ramp for the CONDOR Mk3. Mynaric continues to work through previously announced production delays and has realized near-term improvement in production yields and supply chain-related bottlenecks. Production delays of CONDOR Mk3 were caused by lower than expected production yields and supplier shortages of key components. Current shipments of the CONDOR Mk3 free space optical communications system will be part of the United States Space Development Agency (SDA) Tranche 1 program. Mynaric was selected by Northrop Grumman as the sole supplier of optical communications terminals for the SDA's Tranche 1 Transport and Tracking Layer programs and by York Space Systems for the SDA's Tranche 1 Transport Layer. Mynaric was also selected by Loft Federal to supply the CONDOR Mk3 terminals to NExT – the SDA's Experimental Testbed. In addition, Mynaric continues to pursue opportunities that explore the use of free-space optical communications for additional space programs. Mynaric has been recognized as a key development partner in Phase 2 of DARPA's Space-BACN program, was selected by the European Space Agency (ESA) to investigate optical technologies for next generation high-throughput optical inter-satellite links and was selected by the German government for multiple projects to develop quantum communication capabilities. In addition, Mynaric continues to diligently pursue additional capital sources to secure on-going operations and production ramp.공시 • Aug 27+ 1 more updateMynaric AG Announces Management ChangesThe board of Mynaric AG announced the appointment of Andreas Reif with immediate effect as member of the management board and Chief Restructuring Officer. In his role as CRO, Andreas Reif will be integral to reducing costs and near-term cash consumption while working closely with customers to meet their requirements. Prior to joining Mynaric, Andreas Reif served in executive financial and operational roles and as a key advisor forindustrial manufacturing companies throughout Germany. Mynaric announced that the supervisory board and the chief executive officer, Mustafa Veziroglu, jointly decided on the termination of the office of Mustafa Veziroglu as CEO and member of the management board of Mynaric with immediate effect.공시 • Aug 20+ 1 more updateMynaric Announces Departure of Stefan Berndt Von-Bülow as CFOMynaric announced the voluntary departure of CFO Stefan Berndt von-Bülow for personal reasons, effective last week. Berndt von-Bülow has been with Mynaric since 2018 and assumed the role as CFO in 2020. As CFO, Berndt von-Bülow made significant contributions to the company's financial strategy and operations, investor relations, several capital raises, significant debt financing, and, particularly Mynaric's listing on Nasdaq in November 2021, during a time of significant growth and transformation. Mynaric has initiated a global search for a new CFO. In the interim, the two remaining members of the management team, Mustafa Veziroglu and Joachim Horwath, will assume the responsibilities of the CFO.공시 • Jul 23Mynaric AG, Annual General Meeting, Aug 29, 2024Mynaric AG, Annual General Meeting, Aug 29, 2024, at 10:00 W. Europe Standard Time.공시 • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.공시 • Jun 14Mynaric AG to Report Fiscal Year 2023 Results on Jun 20, 2024Mynaric AG announced that they will report fiscal year 2023 results on Jun 20, 2024공시 • May 01Mynaric AG announced delayed 20-F filingOn 04/30/2024, Mynaric AG announced that they will be unable to file their next 20-F by the deadline required by the SEC.공시 • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.이익 및 매출 성장 예측MUN:M0YA - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2026152-22-35-32112/31/202548-53-40-37112/31/202416-72-56-52212/31/20235-94-34-29N/A9/30/20236-83-40-35N/A6/30/20237-73-46-40N/A3/31/20236-74-54-45N/A12/31/20224-74-62-50N/A9/30/20222-68-60-49N/A6/30/20220-62-59-47N/A3/31/20221-54-55-43N/A12/31/20212-45-50-39N/A9/30/2021-1-37-46-33N/A6/30/202114-29-42-27N/A3/31/202112-25-37-22N/A12/31/20201-20-32-17N/A9/30/20201-17-27-14N/A6/30/20204-13-23-12N/A3/31/20205-12-19-10N/A12/31/20190-10-15-8N/A9/30/20194-9N/AN/AN/A6/30/20193-8N/AN/AN/A3/31/20194-8N/AN/AN/A12/31/20185-8-13-8N/A9/30/20185-10N/AN/AN/A6/30/20185-9N/AN/AN/A3/31/20184-8N/AN/AN/A12/31/20173-7N/AN/AN/A9/30/20172-3N/AN/AN/A6/30/20171-2N/AN/AN/A3/31/20171-2N/AN/AN/A12/31/20161-2N/A-2N/A12/31/20152-1N/A-1N/A12/31/201410N/A0N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: M0YA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: M0YA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: M0YA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: M0YA 의 수익(연간 79.4%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: M0YA 의 수익(연간 79.4%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: M0YA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YCapital-goods 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/02/27 09:55종가2025/02/14 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Mynaric AG는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Austin MoellerCanaccord GenuityZafer RüzgarPareto SecuritiesJuergen WagnerStifel, Equities Research
공시 • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.
공시 • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.
공시 • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.
공시 • Feb 18+ 1 more updateMynaric AG(NasdaqGS:MYNA) dropped from NASDAQ Composite IndexMynaric AG has been dropped from the NASDAQ Composite Index.
공시 • Feb 14Mynaric Announces Receipt of Delisting Notice from NasdaqMynaric announced that it received a delisting notification dated February 10, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market Inc. As previously disclosed, on February 7, 2025, Mynaric's management board, with the approval of its supervisory board, resolved on a financial restructuring by proceedings under the German Corporate Stabilization and Restructuring Act (Gesetz über den Stabilisierungs- und Restrukturierungsrahmen für Unternehmen) and notified the competent Munich Local Court - Restructuring Court - of such restructuring project (the "StaRUG Proceeding").On February 10, 2025, Mynaric received the Delisting Notice from Nasdaq notifying Mynaric that, as a result of the StaRUG Proceeding and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that Mynaric's American Depositary Shares representing its ordinary shares (the "ADS") will be delisted from Nasdaq. The Delisting Notice also advises Mynaric of its right to appeal Nasdaq's determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. Mynaric does not intend to pursue an appeal. Trading of the ADS will be suspended at the opening of business on February 18, 2025. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the ADS from listing and registration on Nasdaq. Nasdaq has previously notified Mynaric that it is no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) for failing to maintain a minimum market value of $50 million in listed securities, (ii) Nasdaq Listing Rule 5250(c)(2) for not filing an interim balance sheet and income statement as of and for the end of its second quarter on Form 6-K within six months following the end of Mynaric's second quarter, (iii) Nasdaq Listing Rule 5620(a) for failing to hold an annual meeting of shareholders within twelve months after the end of the Mynaric's fiscal year, and (iv) Nasdaq Listing Rule 5450(a)(1) for not meeting the minimum closing bid price of $1.00 per share of the ADS.
공시 • Jan 16Mynaric AG, Annual General Meeting, Feb 21, 2025Mynaric AG, Annual General Meeting, Feb 21, 2025, at 10:00 W. Europe Standard Time.
공시 • Jan 04Mynaric AG Updates Earnings Guidance for the Full Year 2024Mynaric AG updated earnings guidance for the full year 2024. For the year, the company anticipates IFRS-15 revenue of EUR 14.1 million compared to previous guidance of a range estimating between EUR 16.0 million to EUR 24.0 million. The guidance decrease reflects shipments of CONDOR Mk3 terminals, originally expected to ship in late 2024, to slip into early 2025, due to shortages of key components from suppliers. These delays resulted in approximately EUR 2.6 million of revenue for terminals previously expected to ship in 2024 now expected to ship and revenue recognized in early 2025. Operating loss: the previous Company guidance of a range of operating loss estimating to range between a loss of EUR 55.0 million to EUR 50.0 million is unchanged.
공시 • Nov 05Mynaric AG, Annual General Meeting, Dec 11, 2024Mynaric AG, Annual General Meeting, Dec 11, 2024, at 10:00 W. Europe Standard Time.
공시 • Nov 01Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Files Against Mynaric AGBronstein, Gewirtz & Grossman, LLC announced that a class action lawsuit has been filed against Mynaric AG (Mynaric) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mynaric securities between June 20, 2024, and October 7, 2024, inclusive (Class Period). The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) lower-than-expected production yields and component supplier shortages of key components were causing production delays for Mynaric's CONDOR Mk3 product; (2) the foregoing issues were likely to have a material negative impact on the Company's revenue growth and cause the Company to incur an operating loss; (3) as a result, Mynaric was unlikely to meet its own previously issued financial guidance for fiscal year 2024; (4) accordingly, the Company's business and/or financial prospects were overstated; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.
공시 • Oct 08Mynaric Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed SecuritiesMynaric AG announced that it received a notification letter dated October 2, 2024 (the ‘Deficiency Letter’) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the ‘Nasdaq’) notifying that Mynaric is no longer in compliance with the Nasdaq continued listing criteria, including the Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum of $50 million in market value of listed securities (the ‘MVLS Requirement’). Nasdaq also determined that Mynaric does not meet the alternatives of total assets and total revenue for continued listing. The Deficiency Letter has no immediate effect on the listing of Mynaric’s American Depositary Shares representing its ordinary shares (the ‘ADS’), which continue to trade under the symbol ‘MYNA.’ The Deficiency Letter provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), Mynaric has a period of 180 calendar days from the date of the Deficiency Letter, or until March 31, 2025, to regain compliance with the MVLS Requirement. During this period, the ADS will continue to trade on Nasdaq. Nasdaq will deem Mynaric to have regained compliance with the MVLS Requirement if at any time during this compliance period Mynaric’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days. In the event Mynaric does not regain compliance with the MVLS Requirement by March 31, 2025, Mynaric will receive written notification from Nasdaq that Mynaric’s ADS are subject to delisting. At that time, Mynaric may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if Mynaric does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. In such event, Mynaric may also seek to apply for a transfer to The Nasdaq Capital Market if it meets the requirements for continued listing thereon. Mynaric is reviewing its options for regaining compliance with the MVLS Requirement and for remedying other future potential non-compliances with Nasdaq continued listing requirements. There can be no assurance that Mynaric will be able to regain compliance with the MVLS Requirement or other Nasdaq continued listing requirements in a timely fashion, in which case its securities would be delisted from Nasdaq.
공시 • Sep 17Mynaric Advances Production of CONDOR Mk3Mynaric announced the successful advancement of the company's volume production ramp for the CONDOR Mk3. Mynaric continues to work through previously announced production delays and has realized near-term improvement in production yields and supply chain-related bottlenecks. Production delays of CONDOR Mk3 were caused by lower than expected production yields and supplier shortages of key components. Current shipments of the CONDOR Mk3 free space optical communications system will be part of the United States Space Development Agency (SDA) Tranche 1 program. Mynaric was selected by Northrop Grumman as the sole supplier of optical communications terminals for the SDA's Tranche 1 Transport and Tracking Layer programs and by York Space Systems for the SDA's Tranche 1 Transport Layer. Mynaric was also selected by Loft Federal to supply the CONDOR Mk3 terminals to NExT – the SDA's Experimental Testbed. In addition, Mynaric continues to pursue opportunities that explore the use of free-space optical communications for additional space programs. Mynaric has been recognized as a key development partner in Phase 2 of DARPA's Space-BACN program, was selected by the European Space Agency (ESA) to investigate optical technologies for next generation high-throughput optical inter-satellite links and was selected by the German government for multiple projects to develop quantum communication capabilities. In addition, Mynaric continues to diligently pursue additional capital sources to secure on-going operations and production ramp.
공시 • Aug 27+ 1 more updateMynaric AG Announces Management ChangesThe board of Mynaric AG announced the appointment of Andreas Reif with immediate effect as member of the management board and Chief Restructuring Officer. In his role as CRO, Andreas Reif will be integral to reducing costs and near-term cash consumption while working closely with customers to meet their requirements. Prior to joining Mynaric, Andreas Reif served in executive financial and operational roles and as a key advisor forindustrial manufacturing companies throughout Germany. Mynaric announced that the supervisory board and the chief executive officer, Mustafa Veziroglu, jointly decided on the termination of the office of Mustafa Veziroglu as CEO and member of the management board of Mynaric with immediate effect.
공시 • Aug 20+ 1 more updateMynaric Announces Departure of Stefan Berndt Von-Bülow as CFOMynaric announced the voluntary departure of CFO Stefan Berndt von-Bülow for personal reasons, effective last week. Berndt von-Bülow has been with Mynaric since 2018 and assumed the role as CFO in 2020. As CFO, Berndt von-Bülow made significant contributions to the company's financial strategy and operations, investor relations, several capital raises, significant debt financing, and, particularly Mynaric's listing on Nasdaq in November 2021, during a time of significant growth and transformation. Mynaric has initiated a global search for a new CFO. In the interim, the two remaining members of the management team, Mustafa Veziroglu and Joachim Horwath, will assume the responsibilities of the CFO.
공시 • Jul 23Mynaric AG, Annual General Meeting, Aug 29, 2024Mynaric AG, Annual General Meeting, Aug 29, 2024, at 10:00 W. Europe Standard Time.
공시 • Jun 21Mynaric Provides Earnings Guidance for the Full Year 2024Mynaric provided earnings guidance for the full year 2024. For the fiscal year 2024, revenue outlook is driven by shipments of CONDOR Mk3 units to multiple customers. This outlook assumes it is able to ramp to its current production plans. This outlook remains at the lower end of the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately €65 million). The company expects its operating loss for the fiscal year 2024 to decrease significantly from last year's level due to higher revenue levels. This outlook remains in-line with the most recent published analyst estimates for 2024 (for which the arithmetic average is approximately -€36 million). The outlook is based on the current projected production ramp and current liquidity projection. Should Mynaric experience either a pushout in its production schedule, fail to secure new orders as planned or incur delays in securing new orders from customers, there is a high likelihood the company could need to raise additional capital. Mynaric is also considering pursuing multiple alternative options in order to secure its cash needs and bolster its long-term success.
공시 • Jun 14Mynaric AG to Report Fiscal Year 2023 Results on Jun 20, 2024Mynaric AG announced that they will report fiscal year 2023 results on Jun 20, 2024
공시 • May 01Mynaric AG announced delayed 20-F filingOn 04/30/2024, Mynaric AG announced that they will be unable to file their next 20-F by the deadline required by the SEC.
공시 • Nov 12Mynaric Provides Earnings Guidance for the Full Year 2023Mynaric provides earnings guidance for the full year 2023. The company now expects full-year 2023 IFRS-15 revenue to remain around the same level as 2022 revenue of EUR 4.4 million compared to previous guidance of a significant increase. The guidance decrease is due to the production delay of CONDOR Mk3 that was previously scheduled to start in fourth quarter 2023. The company now expects full-year 2023 operating loss to be around the same level as last year compared to previous guidance of a moderate decrease relative to the EUR 73.8 million operating loss reported for full-year 2022.